Pfizer reports uptake for cancer-therapy Ibrance

Pfizer reports uptake for cancer-therapy Ibrance

Sales of the new cancer drug topped expectations since its February launch.

Medtronic agrees to consent decree

The manufacturer's SynchroMed drug-infusion pump was associated with 14 deaths.

PCSK9 antibodies are safe and effective, analysis concludes

PCSK9 antibodies reduced overall mortality and lowered LDL cholesterol levels in more than 10,000 patients in Phase-II/III clinical trials.

Five things for pharma marketers to know: Tuesday, April 28

Five things for pharma marketers to know: Tuesday, April 28

Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid

FDA says Amgen cancer data can't support accelerated approval

FDA says Amgen cancer data can't support accelerated approval

Briefing materials released before Wednesday's panel review indicate the regulator wants clearer data to assess Amgen's experimental melanoma treatment.

Apple Watch — do you love it?

We know it's early days (the smartwatch been available for three days to be exact), but we'd like to know how it is going.

Open Payments database draws 1M visitors

The Centers for Medicare and Medicaid Services last year published 4.45 million records about financial relationships between industry and HCPs.

Five things for pharma marketers to know: Monday, April 27

Five things for pharma marketers to know: Monday, April 27

More pharma companies hike drug prices post-acquisition; HCV linked to increased risk of cancer; a combined Teva-Mylan would control 25% of the US generic drug market

Pharma Report: A Sunny Day in Pharmaland

Pharma Report: A Sunny Day in Pharmaland

The year 2014 stunned even the sunniest of pharmaceutical optimists. Read our report

Headliner: Pfizer's mentoring maestro hones his craft

Headliner: Pfizer's mentoring maestro hones his craft

The Healthcare Businesswoman's Association 2015 Honorable Mentor has elevated mentoring to a prominent place.

Tecfidera sales slow, Biogen to maintain "significant" sales force

Tecfidera sales slow, Biogen to maintain "significant" sales force

The drugmaker said its top-selling multiple-sclerosis drug Tecfidera's slowdown in sales is due to competition from Plegridy as well as new patient concerns about risks of a rare brain infection.

Five things for pharma marketers to know: Friday, April 24

Five things for pharma marketers to know: Friday, April 24

An AbbVie hep.-C drug nabbed priority review; Merck's hep.-C drug matches efficacy of Harvoni; Mylan increased its bid to buy Perrigo

Merck HCV med's efficacy matches competitors'

Merck HCV med's efficacy matches competitors'

The drugmaker touted new data for its doublet regimen at the International Liver Congress, but it will likely have to look to the margins to find an underserved patient population.

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

Mylan's generic Sovaldi launches in India

The hepatitis-C drug is being sold under the name MyHep.

Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

Sales rise as Amgen outlines cardiovascular strategy

Sales rise as Amgen outlines cardiovascular strategy

Established products fueled at 12% jump in first-quarter sales.

Actavis case may not serve as Namenda precedent

A court sided with Actavis in one product-hopping lawsuit for acne drug Doryx.

FDA grants Pfizer lung-cancer drug Breakthrough Designation

Xalkori received the designation to treat a new subset of non-small cell lung cancer patients.

Five things for pharma marketers to know: Wednesday, April 22

Five things for pharma marketers to know: Wednesday, April 22

Study finds vaccines still not linked to autism; investments in healthcare start-ups hit record high this year; biosimilars are already bearing down on prices overseas

Partners+Simons CEO takes helm at parent company Myelin Health

Partners+Simons CEO takes helm at parent company Myelin Health

With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.

Almost one-third of physicians participated in an ACO last year: Medscape

Despite increasing income, many doctors are turning away from self-employment.

Omnicom reports boost in Q1 net income

The holding company said pharma and health made up 11% of revenues during the first three months of the year.

Five things for pharma marketers to know: Tuesday, April 21

Five things for pharma marketers to know: Tuesday, April 21

Teva proposes acquisition of Mylan; start-up offers BRCA testing for $249; Botox receives another label expansion

Merck files Keytruda for lung cancer, eyes first-line niche

Merck files Keytruda for lung cancer, eyes first-line niche

Genetic protein PD-L1 could have potential as a biomarker for a first-line treatment.

FDA takes unusual stance on ALS drug

FDA takes unusual stance on ALS drug

The FDA asked private biotech Genervon to release all available clinical trial data for its experimental ALS treatment.

Conflict-of-interest rules spur $23M investment

Conflict-of-interest rules spur $23M investment

Schools spent $23 million to bring conflict-of-interest policies in line with regulations aimed at ensuring federally funded research is unbiased.

J&J to pay $63M in Motrin case

A Massachusetts court upheld a 2013 decision that the drugmaker failed to provide sufficient risk information for Children's Motrin.

Five things for pharma marketers to know: Monday, April 20

Five things for pharma marketers to know: Monday, April 20

Teva eyes Mylan takeover; Keytruda shown to improve survival, shrink tumors in melanoma; ADHD abuse may follow grads into workforce.

Amanda Sheldon, Director, Digital Marketing and Communications, Medtronic Diabetes

Amanda Sheldon, Director, Digital Marketing and Communications, Medtronic Diabetes

Session: Inspiring the Future 40/ Intelligent Connections

graphic TEST

Editor's Desk: And the researchers go wild

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

Five things for pharma marketers to know: Friday, April 17

Five things for pharma marketers to know: Friday, April 17

The FDA approves generic Copaxone; AstraZeneca's experimental lung-cancer drug demonstrates that it can delay disease progression; PhRMA CEO John Castellani to step down

Bob Finkel launches 'agency alternative'

Bob Finkel launches 'agency alternative'

Kane & Finkel co-founder Bob Finkel launched a healthcare consultancy that will seek out limited-commitment projects.

Amgen motion to delay Neupogen biosimilar denied

Amgen's attempt to delay Zarxio was denied by a US District Court, which said the argument was speculative.

Five things for pharma marketers to know: Thursday, April 16

Five things for pharma marketers to know: Thursday, April 16

FDA approves Amgen heart failure drug; Pfizer halts breast-cancer drug trial over positive results; 30% of study participants asked docs about drug after seeing or reading an ad

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Biogen, PatientsLikeMe use Fitbit to better understand MS

Biogen, PatientsLikeMe use Fitbit to better understand MS

The drugmaker and patient network teamed up to establish a formal framework for deploying activity trackers for patients with MS and for capturing that data.

Novartis leukemia drug ups progression-free survival

Late-stage results show Arzerra patients have a median progression-free survival rate almost double that of chemotherapy-only patients.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

J&J reports quarterly boost in drug sales

J&J reports quarterly boost in drug sales

The company reported $7.7 billion in pharma revenue in the first quarter despite a drop in overall sales and profit.

Rockpointe launches new compliance publication

Life Science Compliance Update will address growing compliance concerns in healthcare.

Five things for pharma marketers to know: Tuesday, April 14

Five things for pharma marketers to know: Tuesday, April 14

IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza

US drug spending shows reliance on specialty Rx

US drug spending shows reliance on specialty Rx

Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.

ResearchKit: A Medical Research Revolution?

ResearchKit: A Medical Research Revolution?

Apple is putting the power of clinical trials in our pockets with ResearchKit.

Practice Fusion partners with AstraZeneca

Physicians will be notified when patient care is not meeting national guidelines for COPD and asthma.

GSK considering change to sales compensation model

The British drugmaker is reviewing the patient-oriented sales model it introduced in 2011.

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

WebMD to launch app for Apple's smartwatch

WebMD to launch app for Apple's smartwatch

The small screen makes it a user-friendly medication adherence tool.

Marc Sirockman, Executive Vice President and General Manager, Artcraft Health

Marc Sirockman, Executive Vice President and General Manager, Artcraft Health

Session: The patient view on transformation: empathy, education and empowerment

Five things for pharma marketers to know: Friday, April 10

Five things for pharma marketers to know: Friday, April 10

AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce

Patients do not feel connected to pharma

Patients do not feel connected to pharma

Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.

Making Mobile Patient Portals Useful

Making Mobile Patient Portals Useful

Though it's unlikely that patient portals will ever be accessed as often as mobile banking, ensuring that the patient portal provides obvious value to a patient's experience with a healthcare provider remains an important point.

Pfizer offers grants for PCSK9 research

The drugmaker is calling on researchers to investigate PCSK9s in specific areas of interest.

Doximity to launch Apple Watch app

The app for the smartwatch includes secure encrypted messaging.

Five things for pharma marketers to know: Thursday, April 9

Five things for pharma marketers to know: Thursday, April 9

Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times

Charles "Chuck" Gershman, Founder, President and COO, Kuveda, Inc.

Charles "Chuck" Gershman, Founder, President and COO, Kuveda, Inc.

Session: Intelligent Connections

FDA Onglyza panel review set for Tuesday

FDA Onglyza panel review set for Tuesday

The panel will focus on heart failure hospitalization rates associated with the diabetes medication.

The Delicate Human Side of Marketing Science

The Delicate Human Side of Marketing Science

For all the scientific tools that have fallen into our hands in the past few years, we are still largely falling short in our efforts to influence our audiences' behaviors.

Mylan plans to acquire OTC and generic drugmaker Perrigo

Generic giant Mylan proposed a deal valued at $30 billion to acquire Perrigo Company.

Pharma tablet presentations falling short

A study said many sales presentations fail to resonate with payer audiences.

Hospira gets fifth FDA warning in two years

The company has received seven warning letters since 2010.

Five things for pharma marketers to know: Wednesday, April 8

Five things for pharma marketers to know: Wednesday, April 8

FDA accepts previously rejected Novo Nordisk insulin application; Merck HCV doublet regimen receives Breakthrough designation for patients with kidney disease; researchers say that rising costs for cancer drugs aren't reasonable

High cancer costs associated with better outcomes

High cancer costs associated with better outcomes

Researchers say countries that spend the most on cancer care have better outcomes, but the explanation behind improved mortality is not clear.

How to Make DTC Ad 'Warnings' More Effective

How to Make DTC Ad 'Warnings' More Effective

A more general warning encourages consumers to engage in a personal discussion with their doctor about a drug, and it promotes engagement with longer-format printed or digitally-delivered information.

New guidelines recommend wait-and-see strategy for sinus infections

The American Academy of Otolaryngology said taking antibiotics for sinus infections is a slightly better treatment strategy than waiting it out.

FDA open-data platform gains traction

FDA's application programming interfaces, or openFDA, reached 6,000 users less than a year after its launch.

Five things for pharma marketers to know: Tuesday, April 7

Five things for pharma marketers to know: Tuesday, April 7

Merck funds protein-degrading technology; Shire expects approval for a new ADHD medication in 2017; state biosimilar notification laws focus on subtext

Drugmakers weigh more use of digital

Drugmakers weigh more use of digital

The pharma sales model increasingly relies on key account managers rather than sales reps.

Health Data Ushers in a New Era for Healthcare Communicators

Health Data Ushers in a New Era for Healthcare Communicators

Patients benefit when they can directly access their health data. Studies suggest that direct patient access to healthcare information could improve patient participation in healthcare and possibly quality.

Rituxan may have rare-disease use

The cancer and immunology drug may help patients with a condition that affects two people in every one million.

FDA will study the impact prices have on Rx purchases

The study will include DTC and DTP advertising.

Five things for pharma marketers to know: Monday, April 6

Five things for pharma marketers to know: Monday, April 6

Pfizer exec said biosimilar interchangeability definition not happening anytime soon; AARP launches digital health tech studies with Pfizer and UnitedHealthcare; BMS inks gene therapy collaboration deal

Five things for pharma marketers to know: Friday, April 3

Five things for pharma marketers to know: Friday, April 3

Hedge fund activist challenges Shire patents; CMS issues documents on biosimilars; Astellas Pharma and the University of Texas MD Anderson Cancer Center partner on leukemia treatment

Jill McNair, Director of Education, Outreach and Community Support, CISCRP

Jill McNair, Director of Education, Outreach and Community Support, CISCRP

Session: The patient view on transformation: empathy, education and empowerment

Paul Magill, Senior Advisor, McKinsey & Company

Paul Magill, Senior Advisor, McKinsey & Company

Session: Battle of the Big Idea

CDC examines how US treats ADHD in children

The government agency found that more children are treated with medication than behavioral therapy.

Read the complete 2015 Game Changers digital edition

Read the complete 2015 Game Changers digital edition

Click the above link to access the complete Digital Edition of the 2015 Game Changers issue, with all text, charts and pictures.

Marketing at 24 Frames per Second

Marketing at 24 Frames per Second

Why healthcare brands need to start speaking in video, and how they can do it

Walgreen Co. sues Endo over pay-for-delay

Walgreen alleges Endo conspired to keep generic Opana ER off the market.

Five things for pharma marketers to know: Thursday, April 2

Five things for pharma marketers to know: Thursday, April 2

Celltrion expects its Remicade biosimilar to hit the US this year; Vivus cuts its sales force; BMJ accuses Novartis of interfering with clinical trials

Teva concealed kickbacks in speaker program, former reps allege

Teva concealed kickbacks in speaker program, former reps allege

Two former Teva sales representatives claim the drugmaker used speaker programs to hide kickbacks for prescribing drugs Copaxone and Azilect.

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson, GSK settle dispute over OTC advertising claims

Johnson & Johnson alleged that misleading advertising threatened the $13.2 million in average weekly sales it makes during prime allergy sales season.

Japan seeks more OTC medications

The government is asking consumers which ones they prefer.

FDA finalizes opioid guidance

Opioids lacking abuse-foiling technology will remain available.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Read the complete April 2015 Digital Edition

Read the complete April 2015 Digital Edition

Click the above link to access the Digital Edition of the April 2015 issue of MM&M, with all text, charts and pictures.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters